Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer

Inclusion Criteria: * Patient (e) Age (e) over 18 years * Kidney cancer metastatic or locally advanced * Anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus, another molecule or developing or having obtained authorization in this indication) may be associated with interferon or combined together * Proposed treatment in first line or second line * Brain imaging not finding brain metastases * Having signed the informed consent of study participation * The patient may have received prior anti-angiogenic Exclusion Criteria: * Cancer of the kidney other than primitive * Previous history of cancer other than kidney cancer in complete remission for less than 5 years * Patients under 18 years * Patients whose treatment is associated with chemotherapy * disorders of cognitive functions to existing treatment delivery * Pathology psychiatric evolutionary * Refusal of participation * Patient unable to respond to cognitive tests * Drug use * Heavy drinking (WHO criteria) * History of stroke * History of head trauma * Brain metastases known * MMS below normal compared to existing standards for age and socio-cultural